This prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)–Inhibiting Regimen (CLEAR) Outcomes trial
Bempedoic Acid Market’s sub-segment on cardiovascular illnesses demonstrates how bempedoic acid is being increasingly recognized as a useful tool for reducing overall cardiovascular risks. Individuals who have high blood cholesterol are more vulnerable to heart disease, myocardial infarction, stroke, and ...
“[Bempedoic acid] and [bempedoic acid and ezetimibe] are once-daily, accessible, oral medications that reduce LDL-C and cardiovascular risk, but without the side effects most common to statins. [Bempedoic acid] and [bempedoic acid and ezetimibe] are also the first oral non-statin LDL-C lo...
Bempedoic acid faces the complex scenario of dyslipidemia with an intriguing pharmacological potential that could make it an interesting alternative in the management of LDL-C-related atherosclerotic diseases. In the present work, its biochemical properties and therapeutic potential mainly vs. statins will...